SG11201804993RA - Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes - Google Patents
Selective glucagon receptor agonists comprising a chelating moiety for imaging purposesInfo
- Publication number
- SG11201804993RA SG11201804993RA SG11201804993RA SG11201804993RA SG11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA SG 11201804993R A SG11201804993R A SG 11201804993RA
- Authority
- SG
- Singapore
- Prior art keywords
- sanofi
- frankfurt
- international
- aventis
- main
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307000 | 2015-12-14 | ||
| PCT/EP2016/080553 WO2017102613A1 (fr) | 2015-12-14 | 2016-12-12 | Agonistes des récepteurs du glucagon sélectifs comprenant un fragment chélatant à des fins d'imagerie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804993RA true SG11201804993RA (en) | 2018-07-30 |
Family
ID=55129466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804993RA SG11201804993RA (en) | 2015-12-14 | 2016-12-12 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11046743B2 (fr) |
| EP (1) | EP3389697B1 (fr) |
| JP (1) | JP6986516B2 (fr) |
| KR (1) | KR20180086270A (fr) |
| CN (1) | CN108697767B (fr) |
| AU (1) | AU2016372245B2 (fr) |
| BR (1) | BR112018011892A2 (fr) |
| CA (1) | CA3008052C (fr) |
| DK (1) | DK3389697T3 (fr) |
| ES (1) | ES2846023T3 (fr) |
| HR (1) | HRP20210073T1 (fr) |
| HU (1) | HUE053079T2 (fr) |
| IL (1) | IL259961A (fr) |
| LT (1) | LT3389697T (fr) |
| MX (1) | MX2018007323A (fr) |
| PL (1) | PL3389697T3 (fr) |
| PT (1) | PT3389697T (fr) |
| RU (1) | RU2018125958A (fr) |
| SG (1) | SG11201804993RA (fr) |
| SI (1) | SI3389697T1 (fr) |
| WO (1) | WO2017102613A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004043153B4 (de) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
| CN101282991A (zh) * | 2005-05-26 | 2008-10-08 | 布里斯托尔-迈尔斯斯奎布公司 | N-端修饰的胰高血糖素样肽-1受体调节剂 |
| WO2007139589A1 (fr) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Modulateurs des récepteurs de glp-1 à libération prolongée |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104870009B (zh) * | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
| US9932381B2 (en) * | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
-
2016
- 2016-12-12 MX MX2018007323A patent/MX2018007323A/es unknown
- 2016-12-12 BR BR112018011892-3A patent/BR112018011892A2/pt not_active Application Discontinuation
- 2016-12-12 DK DK16819291.2T patent/DK3389697T3/da active
- 2016-12-12 ES ES16819291T patent/ES2846023T3/es active Active
- 2016-12-12 PT PT168192912T patent/PT3389697T/pt unknown
- 2016-12-12 CA CA3008052A patent/CA3008052C/fr active Active
- 2016-12-12 HU HUE16819291A patent/HUE053079T2/hu unknown
- 2016-12-12 PL PL16819291T patent/PL3389697T3/pl unknown
- 2016-12-12 WO PCT/EP2016/080553 patent/WO2017102613A1/fr active Application Filing
- 2016-12-12 AU AU2016372245A patent/AU2016372245B2/en active Active
- 2016-12-12 JP JP2018549616A patent/JP6986516B2/ja active Active
- 2016-12-12 SG SG11201804993RA patent/SG11201804993RA/en unknown
- 2016-12-12 SI SI201631056T patent/SI3389697T1/sl unknown
- 2016-12-12 KR KR1020187019959A patent/KR20180086270A/ko not_active Application Discontinuation
- 2016-12-12 LT LTEP16819291.2T patent/LT3389697T/lt unknown
- 2016-12-12 CN CN201680081731.0A patent/CN108697767B/zh active Active
- 2016-12-12 EP EP16819291.2A patent/EP3389697B1/fr active Active
- 2016-12-12 US US16/061,421 patent/US11046743B2/en active Active
- 2016-12-12 RU RU2018125958A patent/RU2018125958A/ru not_active Application Discontinuation
-
2018
- 2018-06-12 IL IL259961A patent/IL259961A/en unknown
-
2021
- 2021-01-14 HR HRP20210073TT patent/HRP20210073T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20210073T1 (hr) | 2021-04-30 |
| EP3389697B1 (fr) | 2020-12-16 |
| PL3389697T3 (pl) | 2021-04-19 |
| JP2019508480A (ja) | 2019-03-28 |
| ES2846023T3 (es) | 2021-07-28 |
| SI3389697T1 (sl) | 2021-02-26 |
| WO2017102613A1 (fr) | 2017-06-22 |
| AU2016372245B2 (en) | 2020-07-16 |
| LT3389697T (lt) | 2021-02-10 |
| CN108697767A (zh) | 2018-10-23 |
| RU2018125958A3 (fr) | 2020-06-09 |
| CA3008052A1 (fr) | 2017-06-22 |
| PT3389697T (pt) | 2021-01-22 |
| DK3389697T3 (da) | 2021-01-11 |
| US20200262885A1 (en) | 2020-08-20 |
| US11046743B2 (en) | 2021-06-29 |
| BR112018011892A2 (pt) | 2018-12-04 |
| RU2018125958A (ru) | 2020-01-20 |
| CA3008052C (fr) | 2024-01-02 |
| HUE053079T2 (hu) | 2021-06-28 |
| CN108697767B (zh) | 2022-04-15 |
| MX2018007323A (es) | 2019-01-10 |
| IL259961A (en) | 2018-07-31 |
| KR20180086270A (ko) | 2018-07-30 |
| JP6986516B2 (ja) | 2021-12-22 |
| AU2016372245A1 (en) | 2018-07-26 |
| EP3389697A1 (fr) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201804118VA (en) | Compositions comprising bacterial strains | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408051VA (en) | Cho expression system | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201903427UA (en) | Deodorizing agent comprising zinc neodecanoate | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof |